Addivant(TM) Launches NAUGARD® FOAMPLUS, New Ultra-Low Emissive Antioxidant Solutions for Flexible Polyurethane Foams in Automotive Applications
DANBURY, Conn., May 15, 2017 (GLOBE NEWSWIRE) -- Addivant(TM), a global leader in polymer additive technologies, today announced the launch of the NAUGARD® FOAMPLUS LE solutions, a next generation liquid antioxidant for the polyurethane industry. Developed to meet the challenges faced in automotive applications, the NAUGARD® FOAMPLUS LE portfolio comprises ultra-low emissive stabilization packages enabling the entire value chain to be compliant with the ever-stricter national legislations on vehicle indoor air quality (VIAQ). Addivant will make the announcement during the Chinaplas 2017 exhibition (Booth 9.3M01) May 16-19 in Guangzhou, PR of China.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d8aef4a9-0533-44c3-9ebd-4a1280812210
The NAUGARD® FOAMPLUS LE series has been designed to be inherently more thermally stable to provide excellent scorch protection and polyol stability. Another important advantage is that the liquid antioxidants provide improved handling with a better viscosity profile than existing competitive materials. The new solutions are less volatile than the industry benchmarks at high foaming temperatures, resulting in more than a 90% reduction in VOC (Volatile Organic Compound) & FOG emissions.
"We are excited to launch our NAUGARD® FOAMPLUS LE series this week during Chinaplas." said John Steitz, President and CEO of Addivant. "China is the largest automobile market in the world and it is quickly implementing some of the most stringent environmental and quality standards in the world." The new breakthrough series builds on Addivant's reputation for technology and quality, complementing a comprehensive portfolio of solutions for polyol producers and downstream foamers.
The NAUGARD® FOAMPLUS LE series has been extensively researched and tested to be fully compliant with the VOC and FOG limits set by Germany's VDA 278 emission standard which is part of the delivery specifications of leading automobile companies such as Daimler, BMW, Porsche, and VW. Furthermore, the new solutions maintain or improve upon the other critical performance parameters required by polyol and polyurethane system houses and foam producers.
The new FOAMPLUS LE series is an easy drop-in replacement for existing stabilization packages, allowing customers to switch quickly without any investments or plant modifications. Addivant provides peace of mind to the global polyurethane industry by supporting customer's global standards with worldwide manufacturing and technical support capabilities.
The automotive industry is increasingly replacing traditional materials with polyurethanes to deliver greater comfort, meet higher fuel efficiency standards and provide greater safety and design flexibility. Addivant is well positioned to help the polyurethane industry meet these challenges with the broadest range of specialty solutions in the market.
Addivant(TM) and NAUGARD® are trademarks of Addivant.
Americas: Beverly Kindermann: +1 203 702 6182
Europe: Irfaan Foster: +32 479 991 965
Asia Pacific: Bill Xu: +86 216 032 6822
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Addivant via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00 | Pressmeddelande
Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31 | Pressmeddelande
NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999. "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man
CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00 | Pressmeddelande
CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i
HemChecks avläsare kalibrerad med toppresultat - Regulatorisk20.11.2017 16:18 | Pressmeddelande
HemChecks avläsare kalibrerad med toppresultat Det medicintekniska bolaget HemCheck, som utvecklar ett patientnära test för detektion av hemolys, kan idag meddela att den digitala avläsare som utgör en del av bolagets produktkoncept Helge, kalibrerats med mycket gott resultat. Detta skedde genom studier i egen regi. Avläsaren kan nu färdigställas och produktkonceptet kommer därmed ett steg närmare CE-märkning. Som ett led i att färdigställa bolagets produktkoncept Helge har HemCheck under hösten utfört studier i egen regi med hjälp av blod från frivilliga bloddonatorer. Syftet var att kalibrera avläsaren och på så sätt möjliggöra en patientnära avläsning av hemolys, det vill säga redan på ett tidigt stadium avgöra om blodprovet är användbart och kan ska skickas till analys. -Enkelt utryckt har vi lärt avläsaren att mäta hemolys på våra engångstester. Det är en viktig milstolpe och en stor framgång. Nu känner vi oss redo
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum